June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Use of collagen-hybridizing peptides to assess active fibrosis in 2 mouse models of choroidal neovascularization
Author Affiliations & Notes
  • Peter Westenskow
    Roche Pharma Research and Early Development, Roche Innovation Center, F. Hoffman-La Roche AG, Basel, Switzerland
  • Lucas Bennink
    3Helix.com, Salt Lake City, Utah, United States
  • Richard Foxton
    Roche Pharma Research and Early Development, Roche Innovation Center, F. Hoffman-La Roche AG, Basel, Switzerland
  • Mike Kirkness
    3Helix.com, Salt Lake City, Utah, United States
  • Markus Linder
    Roche Pharma Research and Early Development, Roche Innovation Center, F. Hoffman-La Roche AG, Basel, Switzerland
  • Footnotes
    Commercial Relationships   Peter Westenskow F. Hoffman-La Roche Ltd., Code E (Employment); Lucas Bennink 3Helix.com, Code E (Employment); Richard Foxton F. Hoffman-La Roche Ltd., Code E (Employment); Mike Kirkness 3Helix.com, Code E (Employment); Markus Linder F. Hoffman-La Roche Ltd., Code E (Employment)
  • Footnotes
    Support  F. Hoffmann-La Roche Ltd. (Basel, Switzerland) provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation. Third-party writing assistance was provided by Anne Nunn, PhD, and Ellen M. Ross, PhD, of Envision Pharma Group and funded by F. Hoffmann-La Roche Ltd.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3870. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter Westenskow, Lucas Bennink, Richard Foxton, Mike Kirkness, Markus Linder; Use of collagen-hybridizing peptides to assess active fibrosis in 2 mouse models of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3870.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Subretinal fibrosis causes irreversible vision loss in patients with neovascular age-related macular degeneration (nAMD). Ophthalmic imaging techniques allow detection of fibrosis with limited efficiency and there is a clinical need for novel tools to monitor fibrosis-related changes. We report in vivo imaging of active fibrosis using collagen-hybridizing peptides (CHPs), small molecules that bind to single α-chain collagen structures, allowing identification of collagen remodeling (a hallmark of active fibrosis) in the subretinal space.

Methods : Using 2 independent mouse models (laser-induced choroidal neovascularization [CNV]; JR5558 spontaneous CNV), we investigated the effectiveness of sCy7.5-labeled CHPs to image active fibrotic lesions in vivo. Validation studies assessed correlation between CHP and epithelial mesenchymal transition (EMT) markers, laser intensity and CHP binding in vivo, and between in vivo and ex vivo CHP quantification of active collagen. The antifibrotic effects of a bispecific angiopoietin-2/vascular endothelial growth factor-A antibody (VA2) were examined in vivo by assessing CHP binding in 42-day-old JR5558 mice after 3 weekly VA2 injections versus IgG control (10 mg/kg body weight; days 21, 28, 35; sCy7.5-CHP injected on day 37).

Results : Integration of retinal pigment epithelium (RPE)/choroid flatmount images of JR5558 eyes showed coexpression of CHPs with fibrosis and EMT-related markers, correspondence between sCy7.5-labeled and sCy3-labeled CHP binding, and increased CHP binding in RPE/choroid with age. After laser-induced scarring, sCy7.5-CHP binding in vivo correlated to the intensity of laser and ex vivo CHP (r = 0.76; P = 0.03) and fibronectin (r = 0.69; P = 0.058) binding. In laser-induced CNV, there was decreased CHP binding in vivo and ex vivo at 8 weeks (stabilized scars) versus 1 week after injury. In JR5558 mice treated with VA2, CHP integration detected significantly decreased collagen remodeling (CHP binding in vivo and ex-vivo; p < 0.01) versus IgG control.

Conclusions : CHPs bound specifically to active fibrosis and detected increased collagen remodeling in JR5558 mouse eyes in vivo as they aged, in contrast to reduced binding over time in laser-induced scarring. The antifibrotic effects of dual Ang-2/VEGF-A inhibition were clearly demonstrated using this method, which has potential to support clinical development of nAMD treatments.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×